Pompe Pregnancy Sub-Registry

Summary

This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglucosidase alfa or avalglucosidase alfa) and irrespective of the commercial product with which she may be treated. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Glycogen Storage Disease Type II (GSD-II)
• Pompe Disease (Late-onset)
• Glycogenesis 2 Acid Maltase Deficiency

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

Any age

Sex

Female

Healthy volunteers

Not accepted

Sponsor

Genzyme, a Sanofi Company

Last updated on ClinicalTrials.gov

April 16, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites